Clinical implications of HIV-1 drug resistance in the neurological compartment

A Antinori, Antonella Cingolani, Ml Giancola, F Forbici, Andrea De Luca, Cf Perno

Risultato della ricerca: Contributo in rivistaArticolo in rivista


The tropism of human immunodeficiency virus type 1 (HIV-1) for the central nervous system (CNS) develops early during the course of the infection. Potent antiretroviral therapy has been demonstrated to be effective in controlling the replication of HIV-1 in cerebrospinal fluid (CSF), even though a variable response in this compartment compared with that in plasma has been observed. Different concentrations of antiretroviral drugs are found in CSF and the use of antiretroviral drugs penetrating across the blood-brain barrier is considered to be required for controlling CNS infection in advanced patients, particularly in those with neurological disorders. The compartmentalization of HIV-1 infection in the CNS may affect the treatment response, which may cause a different evolution of viral drug resistance in the 2 compartments. Although HIV-1 resistance testing in CSF is not recommended for the routine management of patients with virological failure, treatment decisions in patients with neurological disorders may require knowledge of the resistance profile of the virus in the CSF.
Lingua originaleEnglish
pagine (da-a)41-44
Numero di pagine4
Stato di pubblicazionePubblicato - 2003


  • AIDS Dementia Complex
  • Anti-HIV Agents
  • Antiretroviral Therapy, Highly Active
  • Biological Availability
  • Blood-Brain Barrier
  • Drug Resistance, Viral
  • Female
  • HIV Infections
  • HIV-1
  • Humans
  • Male
  • Microbial Sensitivity Tests
  • RNA, Viral
  • Sensitivity and Specificity
  • Severity of Illness Index
  • Viral Load
  • Virus Replication


Entra nei temi di ricerca di 'Clinical implications of HIV-1 drug resistance in the neurological compartment'. Insieme formano una fingerprint unica.

Cita questo